Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 24 clinical trials
Pharmacokinetic Study to Evaluate Anti-mycobacterial Activity of TMC207 in Combination With Background Regimen (BR) of Multidrug Resistant Tuberculosis (MDR-TB) Medications for Treatment of Children/Adolescents Pulmonary MDR-TB

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (explores what the body does to the drug), and anti-mycobacterial activity of bedaquiline (TMC207) in children and adolescents (0 months to less than [<] 18 years of age) diagnosed with confirmed or probable pulmonary multidrug resistant tuberculosis (MDR-TB), …

tmc207
pulmonary tuberculosis
extensively drug-resistant tuberculosis
bedaquiline
chest x-ray
  • 94 views
  • 23 Apr, 2021
  • 9 locations
Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients

The purpose of this study is to compare the efficacy and safety of 26 weeks of delamanid (DLM) versus 26 weeks of isoniazid (INH) for preventing confirmed or probable active tuberculosis (TB) during 96 weeks of follow-up among high-risk household contacts (HHCs) of adults with multidrug-resistant tuberculosis (MDR-TB) (index cases). …

rifampin
oophorectomy
absolute neutrophil count
atazanavir
vasectomy
  • 137 views
  • 04 Apr, 2021
  • 27 locations
The Individualized M(X) Drug-resistant TB Treatment Strategy Study

This is a randomized controlled clinical trial comparing treatment success of a gene-derived individualized drug-resistant Tuberculosis regimen to a standard Tuberculosis regimen based on South

antiretroviral
rifampin
pulmonary tuberculosis
extensively drug-resistant tuberculosis
probe
  • 21 views
  • 15 Feb, 2021
  • 1 location
Promoting Engagement in the Drug Resistant TB-HIV Care Continuum in South Africa PRAXIS Study

The goal of the proposed study is to enhance adherence and retention in care for M/XDR-TB HIV patients through enhanced standard of care, targeted transition to outpatient medication self-administration prior to hospital discharge, and use of community adherence groups, with an overarching goal of promoting patient engagement in a care …

  • 55 views
  • 23 Jan, 2021
  • 1 location
Treatment Shortening of MDR-TB Using Existing and New Drugs

The purpose of this study is to compare the efficacy of a 'new treatment regimen including delamanid, linezolid, levofloxacin, and pyrazinamide for nine or twelve months (investigational arm)' and 'the standard treatment regimen including injectables for 20 to 24 months (control arm)' for treating fluoroquinolone-sensitive multidrug-resistant tuberculosis.

fluoroquinolones
linezolid
pyrazinamide
delamanid
treatment regimen
  • 0 views
  • 22 Jan, 2021
  • 1 location
The Effect of 18-month Regimen Containing 6 Anti-tuberculosis Drugs for Patients With MDR-TB

WHO has recommended that multidrug-resistant tuberculosis (MDR-TB, defined as resistance to at least isoniazid (H) and rifampicin (R) be addressed as a public health crisis and enhance capacity to deliver effective treatment and care. According to the 2018 WHO TB Report, the overall treatment success rate of MDR-TB is 55% …

rifampin
pulmonary tuberculosis
extensively drug-resistant tuberculosis
isoniazid
chest x-ray
  • 0 views
  • 23 Jan, 2021
  • 20 locations
Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial

PRACTECAL-PRO is a sub-study of a TB-PRACTECAL clinical trial for multidrug resistant Tuberculosis. It evaluates the effectiveness of TB-PRACTECAL interventions from the patient perspective in terms of their quality of life, shared decision making and satisfaction with services.

linezolid
clofazimine
pretomanid
bedaquiline
moxifloxacin
  • 0 views
  • 16 May, 2021
  • 6 locations
Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T)

The purpose of this study is to assess the efficacy, safety and tolerability of a combination of levofloxacin, linezolid, cycloserine and pyrazinamide (or clofazimine if resistant to pyrazinamide) treatments for 24 to 32 weeks (regimen consisted of clofazimine for 36~44 weeks) in subjects with multidrug-resistant tuberculosis (MDR-TB) compared to WHO …

smear
rifampin
linezolid
pulmonary tuberculosis
pyrazinamide
  • 0 views
  • 24 Jan, 2021
  • 13 locations
Clinical Study on Adoptive Treatment of MDR-TB With Allogeneic T Cells

Brief summary: Allogeneic T cells from healthy donor will be administrated intravenously to patients with the MDR-TBand then the safety and efficacy of T cells will be evaluated.

  • 0 views
  • 22 Jan, 2021
  • 1 location
Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T)-PLUS

The purpose of this study is to assess the efficacy, safety and tolerability of a combination of bedaquiline, linezolid, cycloserine, clofazimine and pyrazinamide treatments guided by PZA sensitivity for 24 to 36 weeks in subjects with fluoroquinolone-resistant MDR-TB .

  • 0 views
  • 29 Jan, 2021
  • 13 locations